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AbstrAct:
Eradication of cancer stem cells to abrogate tumor growth is a new treatment 
modality. However, like normal cells cancer cells show plasticity. Differentiated 
tumor stem cells can acquire stem cell properties when they gain access to 
the stem cell niche.  This indicates that eradicating of stem cells (emptying 
of the niche) alone will not lead to eradication of the tumor. Treatment 
should be directed to cancer stem cells ànd more mature cancer cells.
The discovery of cancer stem cells for solid tissues 
evoked an enormous research effort into this new avenue of 
treatment options [1]. Especially, the properties of cancer 
stem cells gained an enormous welcome because several 
in vivo findings could be explained. Cancer stem cells 
are resistant to irradiation and survive chemotherapeutic 
agents due to mechanisms very well known from normal 
stem cells.  This in contrast to their mature offspring. 
Those stem cell features explain that- in a high percentage 
of patients- after killing the more mature tumor cells with 
these treatment modalities, the tumor will regrow. The 
first compounds that show specific killing of cancer stem 
cells are reported [2]. Such experiments suggest that the 
cancer stem cells could be killed given the right drugs are 
used [3]. Salinomycin one of the reported cancer stem cell 
drugs make stem cells that express multidrug transporters 
again vulnerable for chemotherapeutic drugs by blocking 
the  drug  expelling ABC-transporter  [4].  Expression  of 
the ABCB5 transporter was reported to be confined to 
melanoma stem cells [5] and used as a target to eradicate 
cancer  stem  cells[6].  Also  ALDH  positive  cells  were 
shown to be enriched in tumor initiating cells[7].
However,  for  melanoma  the  cancer  stem  cell 
concept is challenged. Initially it was demonstrated using 
NOD/SCID mice that one in approximately one million 
cancer cells was able to evoke a tumor in those mice [8-
10]. This frequency was challenged when other recipient 
mice were used and the tumor cells were implanted in 
matrigel  [11-13].  This  got  recently  a  follow  up  with 
CD271 positive melanoma cells were the tumor initiating 
cells as deduced from an impressive number of different 
cancer cell lines cultured in vitro but also from cancer 
cells directly obtained from freshly excised tumors [14]. 
The ABCB5 positive fraction could be further enriched 
when the expresion of the VEGFR was taken into account 
[15]. However, this was challenged by other researchers 
[16].
One reason that increases tumor initiating cell 
frequency is the immune status of the mouse used for 
those experiments. Initially NOD/SCID mice that lack 
B- and T-lymphocytes were used.  Later on more highly 
immunocompromised NOD/SCID interleukin-2 receptor 
gamma chain null (Il2rγ(-/-) mice, which also lack NK 
cells were used. Such studies clearly demonstrate that 
heterogeneity  exists  in  tumors:  a  population  of  cells 
that initiates tumors due to lack of immune surveillance 
whereas a less abundant population resists a better 
equipped immune system.  Another  reason  for  this 
difference in frequency of cancer initiating cells could 
rely in the plasticity of stem cells. The normal route for 
a stem cell is to differentiate from stem cell to mature 
tissue cells and is paved with several proliferation and 
maturation/differentiation  steps.  Several  points  in  this 
differentiation are believed to be unidirectional, once 
taken no return is possible (lineage-commitment) [17]. 
Observed transdifferentiation was shown to be due to 
fusion of implanted stem cells with the diseased muscle or 
liver cells [18-20]. There are, however, data out that this 
is not as strict as propagated. Hematopoietic stem cells 
were able to dedifferentiate and become liver cells [21]. 
Knocking down JARID1B  in slow cycling melanoma cells 
exhausted the tumor However, expression of JARID1B 
is dynamic since negative cells can become JARID1B 
positive  [10].  Fibroblasts  could  transdifferentiate  into 
cardiomyocytes  [22].  Fibroblasts  were  even  able  to 
become blood cells without reprogramming into an iPS cell 
first [23] and endothelial cells could simply be converted Oncotarget 2011; 2:  99 - 101 100 www.impactjournals.com/oncotarget
into multipotent stem-like cells by transforming growth 
factor β2 or bone morphogenetic protein 4 [24]. Also in 
the spermatogonial development more differentiated cells 
can go back to the stem cell state when the stem cell niche 
is emptied and the number of stem cells is decreased. 
Moreover, transient amplyfying cells in the gut require 
again stem cell properties when they contact paneth cells 
that supply them with Wnt and rescue the stem cell status. 
In this way the normal number of stem cells is recovered 
by differentiated stem cells that regain stem cell properties 
[25].  For  melanoma  such  a  mechanism  could  also  be 
applicable. Dedifferentiation of more differentiated cells 
will level a shortage of stem cells. Just like a chameleon 
changes its color depending on the circumstances. If 
present, such plasticity would have major implications 
for therapeutic approaches that target only cancer stem 
cells. A combination therapy of destroying cancer stem 
cells as well as more mature progeny could wipe out the 
source of cancer cells. Moreover, as indicated above that 
more immune mice reject more tumorinitiating cells, 
enforcement of the immune system should aid in better 
survival of patients [26].
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